home / stock / hnsbf / hnsbf news

HNSBF News and Press, Hansa Biopharma AB From 04/17/19

Stock Information
Company Name: Hansa Biopharma AB
Stock Symbol: HNSBF
Market: OTC
Menu
HNSBF HNSBF Quote HNSBF Short HNSBF News HNSBF Articles HNSBF Message Board
Get HNSBF Alerts

News, Short Squeeze, Breakout and More Instantly...
HNSBF - Notice to Annual General Meeting in Hansa Biopharma AB (publ)

MALMÖ, Sweden , April 17, 2019 /PRNewswire/ -- Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund , summons to Annual General Meeting on Wednesday 22 Maj 2019 at 17.00 CEST at the auditorium next to the company's premises, Scheelevägen 22, Lund, S...
HNSBF - Hansa Biopharma divests its stake in Genovis and receives approval to commence imlifidase Phase 2 trial

Hansa Biopharma ( OTC:HNSBF )  divests its entire equity stake in Genovis ( OTCPK:GEOVF ) for SEK 89M (c.$9.6M). More news on: Hansa Biopharma AB, Genovis AB (publ), Healthcare stocks news, Read more ...

HNSBF - Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome

LUND, Sweden , April 15, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it received Clinical Trial Application and Ethics Committee approvals in Europe for the compa...

HNSBF - Hansa Biopharma Divests its Equity Holding in Genovis

LUND, Sweden , April 15, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it has divested its entire equity stake in Genovis AB (NASDAQ Stockholm: GENO). The transacti...
HNSBF - Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation

LUND, Sweden , March 26, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it received Clinical Trial Application and Ethics Committee approvals for the company's Phase 2 ...

HNSBF - Hansa Biopharma Announces Selection of NiceR Lead Candidate

LUND, Sweden , March 21, 2019 /PRNewswire/ --– Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the company has selected a lead candidate for clinical development from its NiceR progra...

HNSBF - Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference

LUND, Sweden , March 6, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that Søren Tulstrup, President and CEO of Hansa Biopharma, will present a...
HNSBF - Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX(TM) (imlifidase)

LUND, Sweden , March. 1, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA),   the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the European Medicines Agency (EMA) has accepted the Company's Marketing Authorization Appl...

Previous 10 Next 10